ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review.Journal of the National Cancer Institute · 2026Pooled it
- Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial.Genome medicine · 2025Trial
- Advanced Versus Invasive Breast Cancer Risk in a Screening Population: Implications for Risk-based Prevention and Screening Strategies.Journal of general internal medicine · 2026Article
- Advancing Evidence of the Associations between specific Benign Breast Diagnoses and Future Breast Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- ABUS-based glandular tissue component classification for breast cancer risk prediction in Chinese women with dense breasts: a retrospective study.BMC medical imaging · 2026Article
- Comparing Breast Cancer and Cardiovascular Risk among Women Undergoing Screening Mammography: Why Are Statins More Widely Accepted Compared with Chemoprevention?Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Five-Year Absolute Risk-Based and Age-Based Breast Cancer Screening in the US.JAMA network open · 2026Article
- Effect of race and ethnicity on advanced breast cancer risk prediction model performance.NPJ digital medicine · 2025Article
- Interplay of BMI and volumetric breast density measures and breast cancer risk for black and white women.Breast cancer research : BCR · 2025Article
- Racial Differences in Screening Eligibility by Breast Density After State-Level Insurance Expansion.JAMA network open · 2025Article
- Radiomic Parenchymal Phenotypes of Breast Texture from Mammography and Association with Risk of Breast Cancer.Radiology · 2025Article
- Polygenic risk scores stratify breast cancer risk among women with benign breast disease.Journal of the National Cancer Institute · 2025Article
- Subgroups varying in risk and density highlight the potential for stratified breast cancer screening.European journal of cancer (Oxford, England : 1990) · 2025Article
- The breast cancer genetic testing experience: probing the potential utility of an online decision aid in risk perception and decision making.BMC cancer · 2025Article
- Screening Mammography for 40-Year-Old Women-Whose Decision?JAMA internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeWe extended the Breast Cancer Surveillance Consortium (BCSC) version 2 (v2) model of invasive breast cancer risk to include BMI, extended family history of breast cancer, and age at first live birth (version 3 [v3]) to better inform appropriate breast cancer prevention therapies and risk-based screening.
methodsWe used Cox proportional hazards regression to estimate the age- and race- and ethnicity-specific relative hazards for family history of breast cancer, breast density, history of benign breast biopsy, BMI, and age at first live birth for invasive breast cancer in the BCSC cohort. We evaluated calibration using the ratio of expected-to-observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC).
resultsWe analyzed data from 1,455,493 women age 35-79 years without a history of breast cancer. During a mean follow-up of 7.3 years, 30,266 women were diagnosed with invasive breast cancer. The BCSC v3 model had an E/O of 1.03 (95% CI, 1.01 to 1.04) and an AUROC of 0.646 for 5-year risk. Compared with the v2 model, discrimination of the v3 model improved most in Asian, White, and Black women. Among women with a BMI of 30.0-34.9 kg/m
conclusionThe BCSC v3 model updates an already well-calibrated and validated breast cancer risk assessment tool to include additional important risk factors. The inclusion of BMI was associated with the largest improvement in estimated risk for individual women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.